Is scorpion antivenom cost-effective as marketed in the United States?

Armstrong EP, Bakall M, Skrepnek GH, Boyer LV

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
24055550

DOI
10.1016/j.toxicon.2013.09.001

Indexing Status
Subject indexing assigned by NLM

MeSH
Antivenins /economics; Costs and Cost Analysis; Decision Support Techniques; Marketing; Scorpion Venoms /immunology; United States

AccessionNumber
22014004287

Date bibliographic record published
27/01/2014